ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

N/ACompletedNCT00168168

Alberta Health services60 enrolled

Overview

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Peripheral Stem Cell/Marrow Transplant

Interventions

G-CSF/FilgrastimDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * over age 18 * autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular Exclusion Criteria: * age below 18 years * sensitive to G-CSF

Locations (1)

Cross Cancer Institute

Edmonton, Alberta, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.